Hayward, United States
OptiScan Biomedical Corporation, founded in 1994 and headquartered in Hayward, California, is a biotechnology company specializing in precision glucose monitoring solutions targeted at Intensive Care Units (ICU) and Coronary Care Units (CCU). The company is known for its flagship product, the OptiScanner, an automated bedside device that performs continuous glucose monitoring to aid healthcare professionals in managing the glucose levels of critically ill patients.
Operating within the Biotechnology and Health Care industries, OptiScan's technology addresses a critical need in critical care settings by offering reliable, automated, and frequent glucose level measurements. The company's tagline, "Precision Glucose Monitoring for ICU and CCU Care," reflects its focused approach in addressing the specific needs of hospital settings.
The company secured its last known major funding round with a $20.00M Series E investment on 20 March 2019, which underscores investor confidence in their technology and market potential. With its established presence and specialized product offering, OptiScan Biomedical Corporation is well-positioned for continued growth and innovation in critical care technology.
Apollon
